The FDA approves a subcutaneous formulation of Johnson & Johnson’s (JNJ -1.9%)
multiple myeloma med Darzalex (daratumumab). Originally, the
CD38-directed cytolytic antibody was administered via intravenous
infusion.
The formulation is based on Halozyme’s (HALO +0.6%) Enhanze drug delivery technology.
J&J in-licensed exclusive global rights to the product from Genmab A/S (GMAB +2.6%) in August 2012.
https://seekingalpha.com/news/3567772-fda-oks-subcutaneous-version-of-j-and-js-darzalex
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.